System4 Technologies: Universal therapy device for COVID-19, COVID-19 mutations, and other virus variants unveiled

• Initial
  off-label-use applications with a special plasma design are promising.
• Possible use in
  intensive care medicine and treatment of long COVID.
• Planned
  large-scale study on universal use against coronaviruses and other RNA viruses.

BAD ZWISCHENAHN, GERMANY – EQS Newswire – 26 April
2021 – The life science company System4 Technologies
GmbH has developed a new therapy device for the treatment of Covid patients.

 

The device, named PI-RNA, is designed to enable
universal and fast deactivation of coronaviruses and influenza viruses, their
mutations and new variants by means of  a special cold atmospheric plasma procedure.
“The so-called CAP (Cold Atmospheric Plasma) – technology transfers
electrostatically atmospheric anions, in high numbers and densities, into and
around the body of the patient. This is achieved through a newly developed
plasma design and transfer procedure that we have developed in the past eight
months”, says Ilir Guslo, Managing Director of System4 Technologies GmbH. “The
atmospheric anions, which are transferred in a gentle and non-invasive manner,
contain reactive electrons that are presumed to interact with all variants of
the coronavirus and influenza viruses, and inactivate them”, states Guslo
further.

 

In the scientific hypothesis, the anions group
around the spike proteins of the virus. This accumulation of ions around the
spike proteins causes highly reactive hydroxyl radicals (OH·) to form. These
react with the spike proteins and withdraw hydrogen from them, whereby water
(H2O) is formed from the hydroxyl radicals (OH·) and the hydrogen (H). The loss
of hydrogen damages the spike proteins, rendering them incapable of infecting
human cells. The PI-RNA device is intended for use in intensive care medicine
to achieve a significant reduction of the viral load in the lungs, mouth and
pharynx, and to support a fast regeneration of the patient. The developers also
envisage effective post-therapeutic use of the device for the treatment of late
symptoms of COVID-19, also known as long COVID. Research into the use of cold
atmospheric plasma on coronaviruses has been conducted for a considerable time
at the Max Planck Institute and the Fraunhofer Institute for Toxicology and
Experimental Medicine.

 

However, before PI-RNA can be used, the
hypothesis and promising initial indications from off-label-use applications in
Hungary must be confirmed and scientifically verified by a two-phase
double-blind study.

 

“Together with a highly respected clinical research
partner, we are planning to start the phase I clinical study in mid-2021, to
run simultaneously at three national and international sites”, says Dr Benjamin
Seibt, of Genomics, scientific partner of the project.

 

Due to the dynamic development of potentially
harmful Sars-CoV-2 mutations and new variants, worldwide focus has shifted to
universal active agents and therapies to fight the pandemic and for the
post-pandemic period.

 

System4 Technologies is hoping to produce swift
results and solutions, thereby contributing toward a universal virus therapy.